Regencell Bioscience Holdings Limited (RGC)

RGC Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	3.43	3.78	4.8	5.11	0.94	0.43
Research & Development	0.98	0.95	1.47	2.51	0.44	0.39
Operating Expenses	4.4	4.74	6.27	7.62	1.38	0.81
Operating Income	-4.4	-4.74	-6.27	-7.62	-1.38	-0.81
EBT Excluding Unusual Items	-4.4	-4.74	-6.27	-7.62	-1.38	-0.81
Other Unusual Items	0.37	0.37	0.21	0.02	0.03	-
Pretax Income	-4.03	-4.36	-6.06	-7.59	-1.35	-0.81
Earnings From Continuing Operations	-4.03	-4.36	-6.06	-7.59	-1.35	-0.81
Minority Interest in Earnings	-0.06	0.06	0.19	0.15	-	-
Net Income	-4.09	-4.3	-5.87	-7.45	-1.35	-0.81
Net Income to Common	-4.09	-4.3	-5.87	-7.45	-1.35	-0.81
Shares Outstanding (Basic)	494	494	494	487	380	380
Shares Outstanding (Diluted)	494	494	494	487	380	380
Shares Change (YoY)	-	-	1.62%	28.06%	-	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.02	-0.00	-0.00
EPS (Diluted)	-0.01	-0.01	-0.01	-0.02	-0.00	-0.00
Free Cash Flow	-	-4.01	-4.99	-6.05	-0.77	-0.84
Free Cash Flow Per Share	-	-0.01	-0.01	-0.01	-0.00	-0.00
EBITDA	-4.09	-4.43	-5.98	-7.47	-1.35	-0.8
D&A For EBITDA	0.31	0.31	0.29	0.15	0.03	0.01
EBIT	-4.4	-4.74	-6.27	-7.62	-1.38	-0.81
Advertising Expenses	-	1	0.03	0.03	-	-

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q